Sept. 26 Preclinical Quick Takes: $30M for new lung disease lab; plus AI-derived compounds from Auransa, Atomwise, and diabetes candidates

Bayer, Brigham and Mass General open lung disease-focused lab
Bayer AG (Xetra:BAYN) will invest more than $30 million over five years to fund research into new treatments for chronic lung diseases, such as chronic obstructive

Read the full 349 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE